Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Hyperthermia 2Breast Neoplasms 2Uveal Melanoma 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 8pembrolizumab 5Cisplatin 5enfortumab vedotin 3avelumab 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3vinflunine 2Radiotherapy 2Nephroureterectomy 2Immunoglobulin G 2Doxorubicin 2Disulfides 2vandetanib 1tremelimumab 1tocilizumab 1tamibarotene 1relatlimab 1pegfilgrastim 1merphos 1guadecitabine 1genexol-PM 1enzalutamide 1durvalumab 1dehydroftorafur 1atezolizumab 1abexinostat 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ureteral Neoplasms × Hyperthermia, Induced × Clear all
NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡